Get the Stockscreener App
1.15
5.50%
0.06
After Hours:
1.15
Inovio Pharmaceuticals Inc stock is traded at $1.15, with a volume of 2.88M.
It is up +5.50% in the last 24 hours and down -12.88% over the past month.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
See More
Previous Close:
$1.09
Open:
$1.1
24h Volume:
2.88M
Relative Volume:
1.09
Market Cap:
$118.91M
Revenue:
$65,300
Net Income/Loss:
$-84.93M
P/E Ratio:
-0.6733
EPS:
-1.708
Net Cash Flow:
$-83.57M
1W Performance:
-0.86%
1M Performance:
-12.88%
6M Performance:
+9.52%
1Y Performance:
-56.60%
1-Day Range:
$1.07
$1.15
1-Week Range:
$1.07
$1.21
52-Week Range:
$0.5632
$2.72
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.15 | 118.91M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-26 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer - Zacks Investment Research
Inovio advances FDA review: Inovio Pharmaceuticals stock falls 3.77 percent - AD HOC NEWS
Inovio Pharmaceuticals stock fell 4.13 percent before FDA decision - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals stock approaches its October FDA test - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Zacks Investment Research
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Debt to equity ratio of Inovio Pharmaceuticals, Inc. – HAN:GBM - TradingView
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Pharmaceuticals stock trades lower as FDA date nears - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock gains as price crosses 200-day moving average - AD HOC NEWS
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock trades near 52-week midpoint as analysts keep Moderate Buy view - AD HOC NEWS
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com South Africa
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com Nigeria
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms - TradingView
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms - Yahoo Finance
Inovio at H.C. Wainwright conference: FDA review and launch loom By Investing.com - Investing.com India
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP - TradingView
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP - Yahoo Finance
INOVIO at Cantor Fitzgerald healthcare conference: FDA decision nears By Investing.com - Investing.com India
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INOVIO Steps Up Investor Outreach at New York Conferences - MyChesCo
INO Stockholders Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INOVIO to Participate in Upcoming Investor Conferences - Eastern Progress
Inovio Pharmaceuticals Stock Price Forecast. Should You Buy INO? - StockInvest.us
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock gains as analysts see sharp upside - ad-hoc-news.de
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Investor talks begin Sept. 9 as INOVIO joins two conferences - Stock Titan
INOVIO to Participate in Upcoming Investor Conferences - PR Newswire
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio stock holds in low single digits as losses weigh on outlook - ad-hoc-news.de
Inovio Pharmaceuticals Inc. (INO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio: The Final Countdown To A Binary FDA Decision - Seeking Alpha
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio (INO) Results Versus Estimates: Profit Per Share Clears Its Benchmark in Latest Trading; Market Response: The Stock Ends Down 6.92%Pre-Earnings Setup - Vinanet
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Company Profile & Introduction - Moomoo
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.64%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):